Bispecific biotherapeutics are a promising modality for treating cancer, HIV (Human Immunodeficiency Virus), and other autoimmune diseases.
As with any other biotherapeutic, the formulation development process is key to ensuring these drugs remain stable and active when administered to patients.
At Immunocore, Senior Scientist II, Dr Jordan Bye and his team focus on the formulation development of ImmTAX, (Immune Mobilizing Monoclonal TCRs Against X disease), potent novel bispecific molecules, so they remain stable throughout development, manufacturing, and storage until delivery.
Watch this webinar to hear from Dr. Jordan Bye, Senior Formulation Development Scientist II at Immunocore, as he shares approaches and insights into formulating these innovative therapies.
You’ll learn about:
- ImmTAX – Immunocore’s proprietary T-cell bispecific molecules – and how they work
- The different stability considerations for bispecific formulation development and parallels with the formulation of monoclonal antibodies
- How Jordan selects optimal formulations – with data examples from the Prometheus Panta instrument for multi-parameter stability characterization Challenges related to delivery of low dose, potent bispecific therapeutics
Curious about how to use Prometheus Panta for formulation screening? Watch this video.
